Literature DB >> 18679710

PKD1 haploinsufficiency is associated with altered vascular reactivity and abnormal calcium signaling in the mouse aorta.

Nicole Morel1, Greet Vandenberg, Ali K Ahrabi, Nathalie Caron, Fanny Desjardins, Jean-Luc Balligand, Shigeo Horie, Olivier Devuyst.   

Abstract

Mutations in PKD1 are associated with autosomal dominant polycystic kidney disease (ADPKD), which leads to major cardiovascular complications. We used mice with a heterozygous deletion of Pkd1 (Pkd1+/-) and wild-type (Pkd1+/+) littermates to test whether Pkd1 haploinsufficiency is associated with a vascular phenotype in different age groups. Systolic blood pressure measured by the tail-cuff method was similar up to 20 weeks of age, but significantly higher in 30-week-old Pkd1+/- compared to Pkd1+/+. By contrast, similar telemetric recordings were obtained in unrestrained Pkd1+/- and Pkd1+/+ mice. The contractile responses evoked by KCl or phenylephrine were similar in young animals but increased in abdominal aortas of 30-week-old Pkd1+/- mice, and acetylcholine-evoked relaxation was depressed. Basal cytosolic calcium, KCl, and phenylephrine-evoked calcium signals were significantly lower in the Pkd1+/- aortas, whereas calcium release evoked by caffeine or thapsigargin was significantly larger. These changes were paralleled with a significant change in the mRNA expression of Pkd2, Trpc1, Orai1, and Serca2a in the aortas from Pkd1+/- vs. Pkd1+/+. These results are the first to indicate that haploinsufficiency in Pkd1 is associated with altered intracellular calcium homeostasis and increased vascular reactivity in the aorta with compensatory changes in transport proteins involved in the calcium signaling network.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18679710     DOI: 10.1007/s00424-008-0561-y

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  42 in total

Review 1.  Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects.

Authors:  Tevfik Ecder; Robert W Schrier
Journal:  J Am Soc Nephrol       Date:  2001-01       Impact factor: 10.121

2.  Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat.

Authors:  Larissa Lipskaia; Federica del Monte; Thierry Capiod; Sabrina Yacoubi; Lahouaria Hadri; Michel Hours; Roger J Hajjar; Anne-Marie Lompré
Journal:  Circ Res       Date:  2005-08-04       Impact factor: 17.367

Review 3.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

4.  Pharmacological and electrophysiological characterization of store-operated currents and capacitative Ca(2+) entry in vascular smooth muscle cells.

Authors:  Lioubov I Brueggemann; Daniel R Markun; Kyle K Henderson; Leanne L Cribbs; Kenneth L Byron
Journal:  J Pharmacol Exp Ther       Date:  2006-01-13       Impact factor: 4.030

5.  Vascular expression of polycystin.

Authors:  M D Griffin; V E Torres; J P Grande; R Kumar
Journal:  J Am Soc Nephrol       Date:  1997-04       Impact factor: 10.121

6.  Polycystin 1 is required for the structural integrity of blood vessels.

Authors:  K Kim; I Drummond; O Ibraghimov-Beskrovnaya; K Klinger; M A Arnaout
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

7.  Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo.

Authors:  Michel Pelat; Chantal Dessy; Paul Massion; Jean-Pierre Desager; Olivier Feron; Jean-Luc Balligand
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

8.  PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice.

Authors:  Ali K Ahrabi; Sara Terryn; Giovanna Valenti; Nathalie Caron; Claudine Serradeil-Le Gal; Danielle Raufaste; Soren Nielsen; Shigeo Horie; Jean-Marc Verbavatz; Olivier Devuyst
Journal:  J Am Soc Nephrol       Date:  2007-05-02       Impact factor: 10.121

9.  A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy.

Authors:  Denise Hilfiker-Kleiner; Karol Kaminski; Edith Podewski; Tomasz Bonda; Arnd Schaefer; Karen Sliwa; Olaf Forster; Anja Quint; Ulf Landmesser; Carola Doerries; Maren Luchtefeld; Valeria Poli; Michael D Schneider; Jean-Luc Balligand; Fanny Desjardins; Aftab Ansari; Ingrid Struman; Ngoc Q N Nguyen; Nils H Zschemisch; Gunnar Klein; Gerd Heusch; Rainer Schulz; Andres Hilfiker; Helmut Drexler
Journal:  Cell       Date:  2007-02-09       Impact factor: 41.582

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  15 in total

Review 1.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

2.  Fundamental insights into autosomal dominant polycystic kidney disease from human-based cell models.

Authors:  Caroline Weydert; Jean-Paul Decuypere; Humbert De Smedt; Peter Janssens; Rudi Vennekens; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2018-09-13       Impact factor: 3.714

Review 3.  Polycystins and renovascular mechanosensory transduction.

Authors:  Amanda Patel; Eric Honoré
Journal:  Nat Rev Nephrol       Date:  2010-07-13       Impact factor: 28.314

Review 4.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

Review 5.  Polycystic kidney disease.

Authors:  Carsten Bergmann; Lisa M Guay-Woodford; Peter C Harris; Shigeo Horie; Dorien J M Peters; Vicente E Torres
Journal:  Nat Rev Dis Primers       Date:  2018-12-06       Impact factor: 52.329

Review 6.  Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.

Authors:  Vicente E Torres; Alessandra Boletta; Arlene Chapman; Vincent Gattone; York Pei; Qi Qian; Darren P Wallace; Thomas Weimbs; Rudolf P Wüthrich
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-24       Impact factor: 8.237

Review 7.  Does kidney disease cause hypertension?

Authors:  Aldo J Peixoto; Marcelo Orias; Gary V Desir
Journal:  Curr Hypertens Rep       Date:  2013-04       Impact factor: 5.369

8.  Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone.

Authors:  Zoë L S Brookes; Lewis Ruff; Viralkumar S Upadhyay; Linghong Huang; Sony Prasad; Tirupa Solanky; Surya M Nauli; Albert C M Ong
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-10-26       Impact factor: 4.733

Review 9.  Vascular complications in autosomal dominant polycystic kidney disease.

Authors:  Ronald D Perrone; Adel M Malek; Terry Watnick
Journal:  Nat Rev Nephrol       Date:  2015-08-11       Impact factor: 28.314

Review 10.  Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling.

Authors:  Caroline R Sussman; Xiaofang Wang; Fouad T Chebib; Vicente E Torres
Journal:  Cell Signal       Date:  2020-04-23       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.